ISSN 2063-5346
For urgent queries please contact : +918130348310

A Study from South India on the Genetic and Non Genetic variables that influence individual’s various Warfarin Dose requirements

Main Article Content

Bala Tripura Sundari. A, Dr. R.Sivaraj, Sudar Codi.R, Somasundaram.G, Indla. Ravi
» doi: 10.31838/ecb/2023.12.si6.218


The purpose of this study was to examine the effects of genetic and non-genetic variables on the variability of stable warfarin dosages in South Indian patients. Method: The study included 96 participants who had consistent warfarin dosages. A few instances of the clinical and demographic data that was captured were age, BMI, and warfarin indications. Single nucleotide polymorphisms in the CYP2C9*2 and CYP2C9*3 genes were discovered in gDNA utilizing the Biorad MJ Mini TM thermocycler. Results: The daily doses of warfarin needed by individuals with variant CYP2C9*2,*3 genotypes were considerably lower than those of patients with wild-type genotypes. The genotype frequencies for CYP2C9*2 and CYP2C9*3 were 64.6%, 19.8%, and 15.6% for the CC, CT, and TT genotypes, and 39.6%, 39.6%, and 20.8% for the AA, AC, and CC genotypes, respectively. The daily recommended dose of warfarin in patients with homozygous wild-type genotype for CYP2C9 (*1/*1) was (4.07± 1.75 mg), which was noticeably better than the daily recommended doses in patients with *1/*2, *1/*3, and *2/*2, *2/*3, and *3/*3 (1.54 ±1.05 mg, p < 0.001). Conclusion: Warfarin dosage is influenced by both genetic and non-genetic factors. Warfarin dosage may be impacted by both genetic and non-genetic factors, which play a significant role. Individual differences in warfarin dosage are demonstrated by CYP2C9*2 and CYP2C9*3 polymorphisms, as well as by age and body mass index.

Article Details